< Back to News & Events

Presentation of our R&D Strategy and Pipeline – Announcement of a New Development Program

Published on


AUROBAC’s strategy aims to address high unmet medical needs associated with infections in acute hospital settings, amidst the growing antimicrobial resistance (AMR) epidemic.

In this context, AUROBAC announced a new collaboration and license agreement on a Boehringer Ingelheim compound that will be developed as ATX101 for the treatment of septic shock. AUROBAC is also progressing a discovery and early preclinical pipeline to develop innovative products against Gram-negative bacteria.

“With AMR recognized by WHO as one of the foremost global public health threats, there is an urgent and unmet need for new therapies to prevent the deadly consequences of Gram-negative resistant infections in acute hospital settings” said Martin Everett, Ph.D., AUROBAC’s Chief Scientific Officer.  “Our diagnostic-driven strategy and innovative pipeline underscore our dedication to developing a new generation of precision drugs and improving outcomes for patients in urgent need.”

Know more


AUROBAC THERAPEUTICS is proud to be a member of the BEAM Alliance

AUROBAC ©2024 – Legal NoticePrivacy StatementPhoto Credits